We are live on ! Find out more
PHAR

Pharming Group
PHAR

3 hedge funds and large institutions have $2.46M invested in Pharming Group in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 2 → 3 (+1)

0.03% more ownership

Funds ownership: 0% → 0.03% (+0.03%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

17% less capital invested

Capital invested by funds: $2.96M → $2.46M (-$498K)

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.05%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$22.2K
2
Morgan Stanley
Morgan Stanley
New York
+$669

Top Sellers

Rank Fund Capital Flow
1
JAM
JW Asset Management
Florida
-$23.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
JAM
1
JW Asset Management
Florida
$2.43M -$23.8M -1,706,348 -90%
UBS Group
2
UBS Group
Switzerland
$32K +$22.2K +1,592 +174%
Morgan Stanley
3
Morgan Stanley
New York
$1K +$669 +48 New

PHAR Hedge Fund Activity: Q1 2021 in Review

3 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q1 2021, worth a combined $2.46M — down 17% from $2.96M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PHAR positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, adding an estimated $22.2K. The largest seller was JW Asset Management, cutting an estimated $23.8M.

  • 3 institutional investors held Pharming Group (PHAR) as of Q1 2021, up from 2 in Q4 2020.
  • Funds reported $2.46M of Pharming Group stock for Q1 2021, down 17% quarter-over-quarter.
  • 1 fund opened new Pharming Group positions in Q1 2021 and 0 closed out, a net change of +1 holder.
  • The largest Pharming Group buyer in Q1 2021 was UBS Group, an estimated $22.2K added.
  • The largest Pharming Group seller in Q1 2021 was JW Asset Management, an estimated $23.8M sold.

Based on aggregated 13F filings for Q1 2021.